Literature DB >> 18346821

Clinical severity of Alzheimer's disease is associated with PIB uptake in PET.

Timo Grimmer1, Gjermund Henriksen, Hans-Jürgen Wester, Hans Förstl, William E Klunk, Chester A Mathis, Alexander Kurz, Alexander Drzezga.   

Abstract

BACKGROUND: The positron emission tomography (PET) tracer [11C]-Pittsburgh Compound-B ([11C]PIB) allows the in vivo assessment of amyloid plaque burden in the brain. In a cross-sectional study we examined the association between the severity of dementia assessed using the Clinical Dementia Rating scale sum of boxes (CDR-SOB) and [11C]PIB-PET in patients with Alzheimer's disease (AD).
METHODS: Patients with probable AD who had an AD-typical [18F]FDG-PET scan were included. Linear regression analysis in anatomically defined regions-of-interest (ROIs) and correlation analysis using statistical parametric mapping (SPM) were used to determine the association between CDR-SOB and [11C]PIB uptake.
RESULTS: The linear regression analyses showed that the CDR-SOB explained approximately 11-22% of the variance of [11C]PIB uptake. The association attained statistical significance in both frontal, in both anterior cingulate cortices, and in both putamina. The SPM analysis showed a significant association in more widespread regions of the brain, with maxima located in similar areas as in the ROI-analysis.
CONCLUSION: The CDR-SOB score is significantly associated with [11C]PIB uptake in patients with AD. Thus [11C]PIB is a potential surrogate marker of dementia severity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18346821     DOI: 10.1016/j.neurobiolaging.2008.01.016

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  40 in total

Review 1.  Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia.

Authors:  William E Klunk
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

Review 2.  Positron emission tomography imaging in neurological disorders.

Authors:  Marios Politis; Paola Piccini
Journal:  J Neurol       Date:  2012-09       Impact factor: 4.849

Review 3.  Clinical applications of PET amyloid imaging: an update.

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-07       Impact factor: 9.236

4.  Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid.

Authors:  Timo Grimmer; Matthias Riemenschneider; Hans Förstl; Gjermund Henriksen; William E Klunk; Chester A Mathis; Tohru Shiga; Hans-Jürgen Wester; Alexander Kurz; Alexander Drzezga
Journal:  Biol Psychiatry       Date:  2009-03-06       Impact factor: 13.382

5.  Association Between Functional Performance and Alzheimer's Disease Biomarkers in Individuals Without Dementia.

Authors:  Maria Vassilaki; Jeremiah A Aakre; Walter K Kremers; Michelle M Mielke; Yonas E Geda; Mary M Machulda; David S Knopman; Preciosa M Coloma; Barbara Schauble; Prashanthi Vemuri; Val J Lowe; Clifford R Jack; Ronald C Petersen; Rosebud O Roberts
Journal:  J Am Geriatr Soc       Date:  2018-11-21       Impact factor: 5.562

6.  Aβ-related hyperactivation in frontoparietal control regions in cognitively normal elderly.

Authors:  Hwamee Oh; Jason Steffener; Qolamreza R Razlighi; Christian Habeck; Dan Liu; Yunglin Gazes; Sarah Janicki; Yaakov Stern
Journal:  Neurobiol Aging       Date:  2015-08-24       Impact factor: 4.673

Review 7.  Amyloid Imaging: Poised for Integration into Medical Practice.

Authors:  Keshav Anand; Marwan Sabbagh
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

8.  Caspase-3 is enriched in postsynaptic densities and increased in Alzheimer's disease.

Authors:  Natalia Louneva; Julia W Cohen; Li-Ying Han; Konrad Talbot; Robert S Wilson; David A Bennett; John Q Trojanowski; Steven E Arnold
Journal:  Am J Pathol       Date:  2008-09-25       Impact factor: 4.307

Review 9.  Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo.

Authors:  G D Rabinovici; W J Jagust
Journal:  Behav Neurol       Date:  2009       Impact factor: 3.342

10.  Assessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions.

Authors:  Larry G Brooks; David A Loewenstein
Journal:  Alzheimers Res Ther       Date:  2010-09-29       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.